BPC-157

Overview

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide composed of 15 amino acids. It is derived from a protective protein found in human gastric juice, known as BPC (Body Protection Compound). The peptide was first isolated and characterized by researchers at the University of Zagreb, Croatia, under the direction of Professor Predrag Sikiric in the early 1990s.

Unlike many peptides used in research, BPC-157 is remarkably stable in human gastric juice, which is unusual for peptides that typically degrade rapidly in acidic environments. This stability has drawn attention from researchers investigating gastrointestinal healing, musculoskeletal repair, and organ protection. BPC-157 does not require a carrier molecule for activity and has demonstrated efficacy in numerous animal models when administered both systemically and locally.

The peptide has been investigated in over 100 preclinical studies across a wide range of tissue types, including muscle, tendon, ligament, bone, and the gastrointestinal tract. Human clinical evidence, by contrast, is very limited. There was early-phase clinical investigation of a related formulation (PL-14736) for inflammatory bowel disease, but research on BPC-157 has been conducted almost exclusively in animal models, and no Phase 3 trials have been completed.

Mechanism of Action

BPC-157 exerts its biological effects through multiple interconnected pathways, making it a pleiotropic peptide with broad tissue-protective properties.

Nitric Oxide System Modulation

One of the primary mechanisms involves modulation of the nitric oxide (NO) system. BPC-157 interacts with the NO pathway to promote vasodilation and angiogenesis, increasing blood flow to damaged tissues. Research published in Life Sciences (2006) demonstrated that BPC-157 mediates its effects at least partially through the NO system, with NOS inhibitors attenuating some of its protective actions.

Growth Factor Upregulation

BPC-157 has been shown to upregulate the expression of growth hormone receptors in tendon fibroblasts and to promote the FAK-paxillin signaling pathway, which is essential for cell migration and tissue repair. A 2010 study published in the Journal of Physiology and Pharmacology demonstrated that BPC-157 significantly increased the expression of the growth hormone receptor in tendon explants, suggesting a mechanism for its tendon-healing properties.

Anti-inflammatory Activity

The peptide demonstrates potent anti-inflammatory properties by modulating cytokine production and reducing oxidative stress markers. It has been shown to counteract the effects of NSAIDs on the gastrointestinal mucosa, suggesting a gastroprotective role that involves prostaglandin system modulation.

Research Summary

Gastrointestinal Healing

A landmark study by Sikiric et al. (1999), published in the Journal of Physiology Paris, demonstrated that BPC-157 accelerated the healing of experimentally induced gastric ulcers in rats. The peptide promoted mucosal repair and angiogenesis at the ulcer site. Subsequent research by the same group (2003) in the Journal of Pharmacological Sciences confirmed these findings and extended them to intestinal anastomosis healing.

Tendon and Ligament Repair

Chang et al. (2011), publishing in the Journal of Applied Physiology, reported that BPC-157 significantly accelerated the healing of transected rat Achilles tendons. Biomechanical testing revealed improved tensile strength in treated tendons compared to controls. A 2014 study in Journal of Orthopaedic Research by Staresinic et al. further demonstrated that BPC-157 promoted tendon-to-bone healing in a rat rotator cuff model.

Neuroprotective Effects

Klicek et al. (2013), in a study published in Regulatory Peptides, investigated BPC-157 in models of traumatic brain injury and found that the peptide reduced brain edema and improved functional recovery. Additional research by Tudor et al. (2010) in Behavioural Pharmacology demonstrated that BPC-157 exhibited antidepressant-like effects in several animal models, potentially through modulation of the dopaminergic and serotonergic systems.

Cytoprotection

Research by Sikiric et al. (2010) in Current Pharmaceutical Design reviewed BPC-157’s cytoprotective properties, noting its ability to counteract organ damage induced by a variety of toxic agents, including alcohol, NSAIDs, and surgical insults. The peptide appeared to engage endogenous defense mechanisms rather than simply blocking a single pathway.

Dosing in Published Research

BPC-157 has been investigated almost entirely in animal models. There is no completed Phase 3 human trial, and no controlled human study has established a dose for BPC-157 itself for any use. Because human dosing has not been defined in the published literature, specific figures circulating in forums or vendor material are unverified and are not reported here.

Safety and Side Effects

Human safety data for BPC-157 are essentially absent. The compound has not undergone the controlled clinical trials needed to characterize its adverse-effect profile, and the published evidence comes overwhelmingly from rodent studies, where it has generally been reported as well tolerated at the doses tested. Preclinical tolerability cannot be assumed to translate to humans, to long-term use, or to the unregulated material sold under this name. A specific theoretical concern follows from the compound’s own proposed mechanism: BPC-157 is reported to promote angiogenesis, the formation of new blood vessels. Angiogenesis is a normal part of healing, but it is also a process tumors depend on, so a systemically administered pro-angiogenic agent carries a theoretical risk that has not been studied in humans. Injectable BPC-157 sold as a research chemical is also subject to the sterility, identity, and purity problems common to that supply chain.

Current Research Status

BPC-157 is not approved by the FDA or any major regulatory agency for any use, and it is not a lawful dietary-supplement ingredient; the FDA has flagged it as raising significant safety concerns and placed it in a category of substances it considers unsuitable for pharmacy compounding. Research on BPC-157 originates largely from a single laboratory group and remains predominantly preclinical, with no completed Phase 3 trials. It is prohibited in sport by the World Anti-Doping Agency. It should be regarded as an investigational compound whose human efficacy and safety are unestablished.

Further reading: BPC-157 is combined with GHK-Cu, TB-500, and KPV in the KLOW peptide blend.

Frequently Asked Questions